Ionis Pharmaceuticals' ION224 drug successfully demonstrated liver histologic improvement in a mid-stage trial for treating NASH.
Ionis Pharmaceuticals' experimental drug, ION224, has successfully met its primary goal in a mid-stage trial for treating metabolic dysfunction-associated steatohepatitis (MASH), also known as non-alcoholic steatohepatitis (NASH). The drug achieved liver histologic improvement at both doses (120 mg and 90 mg) and demonstrated statistically significant MASH resolution without worsening fibrosis. ION224 showed no significant adverse effects and was well-tolerated for MASH patients.
March 13, 2024
9 Articles